Videregen is a spin-off regenerative medicine company located at the Northwick Park Institute of Medical Research. The company was developed to help overcome the chronic shortage of organs available for transplantation procedures. Videregen’s core technology uses decellularized organ scaffolds seeded with the patient’s own stem cells to create non-immunogenic, regenerative personalised organ replacements.
Platform Purification Technology
Videregen are specialists in platform purification technology. This process produces acellular biological scaffolds from a variety of tissues and organs without significantly changing the natural three dimensional structure of the source material. When seeded onto this scaffold, autologous stem cells respond to the material’s unique topographical properties which provide the signal for them to differentiate into the specific organ cell-types. After implantation, the cells multiply to repopulate the scaffold and develop specific biochemical and physiological functions, therefore creating a living organ from the patient’s own cells.
Videregen are predominantly focused on trachea replacement products. There are a number of different diseases of the trachea, which can lead to life threatening symptoms due to airway obstruction. In most cases, patients suffering from trachea related diseases are treated by being subjected to repeated surgical interventions such as stent insertions. This process has a high rate of failure. Videregen’s proprietary technology removes cells and cellular remnants from donated human tracheas, which can then be used as a substitute for the diseased portion of the patients’ trachea.
In addition, to trachea replacement Videregen also specialise in small bowel replacement products, both of which are orphan indications, followed by liver and kidney replacement products.
The direct financial costs of managing diseases related to these organs is over £5 billion per year. This figure is forever increasing as populations age and lifestyle choices lead to increased incidence of chronic diseases and organ failure.